Cubist Systematic Strategies LLC Sells 3,552 Shares of OrthoPediatrics Corp. $KIDS

Cubist Systematic Strategies LLC cut its position in OrthoPediatrics Corp. (NASDAQ:KIDS) by 17.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,351 shares of the company’s stock after selling 3,552 shares during the quarter. Cubist Systematic Strategies LLC owned approximately 0.07% of OrthoPediatrics worth $403,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Northern Trust Corp increased its holdings in shares of OrthoPediatrics by 0.3% during the fourth quarter. Northern Trust Corp now owns 193,798 shares of the company’s stock valued at $4,492,000 after acquiring an additional 644 shares in the last quarter. Invesco Ltd. boosted its position in OrthoPediatrics by 12.1% in the 1st quarter. Invesco Ltd. now owns 18,349 shares of the company’s stock worth $452,000 after purchasing an additional 1,986 shares in the last quarter. American Century Companies Inc. lifted its position in shares of OrthoPediatrics by 16.1% during the 1st quarter. American Century Companies Inc. now owns 30,658 shares of the company’s stock valued at $755,000 after buying an additional 4,248 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of OrthoPediatrics by 46.8% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,148 shares of the company’s stock valued at $348,000 after buying an additional 4,508 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in OrthoPediatrics by 57.1% in the 4th quarter. Deutsche Bank AG now owns 14,393 shares of the company’s stock valued at $334,000 after purchasing an additional 5,233 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

Wall Street Analysts Forecast Growth

KIDS has been the topic of a number of research reports. JMP Securities set a $35.00 price objective on OrthoPediatrics and gave the company a “market outperform” rating in a report on Friday, August 8th. Wall Street Zen raised OrthoPediatrics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Citigroup reissued a “market outperform” rating on shares of OrthoPediatrics in a research report on Friday, August 8th. Finally, BTIG Research decreased their target price on OrthoPediatrics from $40.00 to $39.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.14.

OrthoPediatrics Stock Down 5.9%

Shares of NASDAQ:KIDS opened at $19.29 on Thursday. The stock’s fifty day simple moving average is $21.00 and its 200-day simple moving average is $21.92. OrthoPediatrics Corp. has a 52-week low of $16.59 and a 52-week high of $33.14. The company has a market capitalization of $483.60 million, a P/E ratio of -10.78 and a beta of 1.06. The company has a quick ratio of 3.43, a current ratio of 6.66 and a debt-to-equity ratio of 0.27.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Tuesday, August 5th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.06. OrthoPediatrics had a negative return on equity of 6.36% and a negative net margin of 18.92%.The firm had revenue of $61.08 million for the quarter, compared to the consensus estimate of $61.40 million. OrthoPediatrics has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Insider Activity at OrthoPediatrics

In other news, CFO Fred Hite acquired 5,076 shares of the business’s stock in a transaction dated Thursday, August 21st. The shares were bought at an average cost of $19.41 per share, for a total transaction of $98,525.16. Following the acquisition, the chief financial officer directly owned 213,065 shares in the company, valued at $4,135,591.65. This trade represents a 2.44% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 32.70% of the stock is currently owned by company insiders.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.